Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study

AbstractHepatitis C virus (HCV) infection is associated with increased cardiovascular risk. We evaluated effects of direct-acting antiviral agents (DAAs) on flow-mediated dilation (FMD), a recognized marker of cardiovascular risk. We evaluated FMD and post-ischemic hyperemia (PIH) in consecutive HCV out-patients before starting DAAs, at the end of treatment (Teot) and 12  weeks thereafter. In 22 HCV subjects (age 64.0 years), baseline FMD was 4.52% ± 1.90 and PIH of 5814.4 (IQR 3786.9–7861.9). At (Teot), all patients showed undetectable levels of HCV-RNA and FMD changed from 4.52%  ± 1.90 to 9.39% ± 4.06 (p <  0.001), with a direct correlation between changes in FMD and baseline HCV-RNA levels (r = 0.494,p = 0.020). In parallel, PIH increased from 5814.4 (IQR 3786.9–7861.9) to 7277.6 (IQR 4579.8–10388.8) (p = 0.019). Twelve weeks afterTeot, all patients had persistently negative HCV-RNA, FMD was 10.9%  ± 4.65 and PIH was 10930.3 (IQR 6254.6–18248.2) suggesting a further significant improvement in these parameters. Results remained significant regardless of the presence of cardiovascular risk factors, whereas FMD changes were not statistically significant in subjects with cirrhosis. A persi stent and significant improvement in endothelial function is observed in HCV patients obtaining viral eradication with DAAs treatment. This might suggest a beneficial effect of DAAs treatment on cardiovascular risk profile of HCV patients.
Source: Internal and Emergency Medicine - Category: Emergency Medicine Source Type: research